Ethan Basch, MD, a self-described triple-threat, discusses incorporating patient-centered outcomes into clinical trials. He begins his presentation by describing a colleague's published research article, Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. The study found that not only did Pazopanib cost an estimated $5800 and Sunitinib $7800, but Pazopanib was superior to Sunitiniib in 11 out of 14 quality-of-life indicators.
Ethan Basch, MD, a self-described “triple-threat,” discusses incorporating patient-centered outcomes into clinical trials. He begins his presentation by describing a colleague’s published research article, “Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma.” The study found that not only did Pazopanib cost an estimated $5800 and Sunitinib $7800, but Pazopanib was superior to Sunitiniib in 11 out of 14 quality-of-life indicators.
Dr Basch goes on to explore the clinical evidence of other studies. He says this kind of information is valuable to patient decision making and estimating comparative benefit-risk between treatments, and because it is currently very difficult to find this type of research.
“For patient decision making, of course, patients wish to know what the experiences of people like them were like in a similar context previously, either within trial context, or real-world or not trial context,” he says.
Patient-reported outcomes (PROs), Dr Basch says, are the “gold standard” in collecting information best known by patients. PROs are reported directly by a patient (and sometimes by a caregiver) without filtering by a health professional.
Patient-centered outcomes (PCOs are also important for meaningful healthcare decision making, especially in specific populations. PCOs are not necessarily patient reported, and PROs are not necessarily patient centered.
Groups like PCORI have particularly honed in on patient-centered research. Dr Basch says any researchers who are funded by PCORI must adhere to their standards, which include engaging “people representing the population of interest and other relevant stakeholders in ways that are appropriate and necessary in a given research context.”
There may be challenges in engaging patient populations in self reporting, but their participation could provide valuable information to support decisions by multiple stakeholders.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More